To ensure patients will use digital health solutions, they need to be at the table when these tools are being designed, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.
To ensure patients will utilize digital health solutions, they need to be at the table when these tools are being designed, said Amila Patel, PharmD, chief clinical officer, Navigating Cancer.
Transcript
Research presented at the annual meeting of the American Society of Clinical Oncology found that patients whose language preference was English were significantly more engaged in digital health solutions than patients whose preference was Spanish. Was language the only barrier or are there other enhancements that need to be made to close that gap?
Beyond the language preferences, and making that integrated into our solution, there are a number of other barriers within these types of populations. I think one of them is around cultural differences. So, often these patients might have concerns about privacy, or how these tools are being used beyond their own use. And so, it really requires kind of a strong commitment and outreach towards these patients to educate them that these tools are really beneficial for their care, and they can help them along their cancer journey.
The other thing, too, is that in the state of Texas, Spanish language patients are often living in rural settings, where there's less access to resources like high broadband use. It also requires us to break down some of those structural barriers, and that requires some commitments from a regulatory and policy perspective, as well.
How do we ensure use of digital health solutions doesn't widen disparities between those who can access them and those who cannot?
I think that there's probably 3 key areas we'd want to address there. So, the first is that patients and their caregivers need to have a seat at the table as we're designing these tools to make sure that they're accessible and they can be easily adopted for them. I think secondly, clinicians need to have the resources to be able to adopt these tools, as well, and make sure that their patients have access to them. And then I think the last thing is, from a technology vendor standpoint, we need to make sure that the people developing and designing these solutions are representative of the populations that they are serving.
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL
January 27th 2025Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.
Read More
An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna
January 25th 2025Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Read More